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Recent trials have shown that recombinant tissue plas-
minogen activator (rt-PA) is an effective thrombolytic
agent in patients with acute myocardial infarction. Be-
cause rt-PA converts plasminogen to plasmin, which is
known to activate complement in vitro, we tested the
hypothesis that rt-PA can induce in vivo activation of
complement. Studies were performed in 12 patients with
acute myocardial infarction. Six control patients had
patent coronary arteries and did not receive rt-PA; these
patients had normal values of the components of the
complement system C4a (409 ± 111 ng/ml) and C511 (8.8
± 1.8 ng/ml) with a slight elevation of C3a (204 ± 6.6
ng/ml) in samples collected before coronary arteriog-
raphy (253 ± 25 minutes after onset of pain). After
coronary arteriography, there was a slight decrease in
the values of C4a (224 ± 37 ng/ml), C5a (7.3 ± 1.3
ng/ml) and C3a (164 ± 35 ng/ml),
The remaining six patients had complete coronary
occlusion and received rt-PA (80 to 150 mg intrave-
nously). In this treated group, before coronary arteri-
Administration of thrombolytic therapy is becoming an in-
creasingly common approach to the treatment of patients
with acute myocardial infarction. Recombinant tissue plas-
minogen activator (rt-PA) is more effective than strepto-
kinase in producing recanalization of acutely occluded coro-
nary arteries (I) and may become the thrombolytic agent of
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ography the values of C4a (406 ± 51.6 ng/ml) and C5a
(8.1 ± 1.9 ng/ml) were normal, and those of C3a were
slightly elevated (250 ± 76 ng/ml). All complement val-
ues obtained before rt-PA were similar to those in the
untreated group. However, after administration of rt-
PA (but before any angiographically detectable reper-
fusion), there was a striking increase in C4a (2,265 ±
480 ng/ml; p < 0.01), C3a (600 ± 89 ng/ml; p < 0.05)
and C5a (30.0 ± 4.5 ng/ml; p < 0.05).
Thus, rt-PA causes an immediate, marked activation
of complement in patients with acute myocardial in-
farction. Measurement of plasma anaphylatoxin levels
may be a useful means of assessing the activity of rt-Pa,
and the degree of complement activation might reflect
the extent of thrombolysis. The significance of rt-
PA-induced complement activation with respect to the
extent of ischemic injury remains to be determined, but
it is conceivable that the anaphylatoxin release might
limit the otherwise beneficial effects of rt-PA.
(J Am Coli Cardiol 1987;10:627-32)
choice. Recombinant tissue plasminogen activator induces
thrombolysis by activating plasminogen to plasmin (2),
However, the proteolytic activity of plasmin is not limited
to fibrin and fibrinogen, but also involves a number of other
proteins including various components of the complement
system. Specifically, in vitro studies have shown that plas-
min can activate component Cl with subsequent activation
of the entire complement cascade (3) and that plasmin also
has the ability to directly cleave and activate C3 (4) and C5
(5). Although the thrombolytic action of rt-PA has been
well characterized, the potential effects of this plasmin-
generating agent on the complement cascade are unknown.
Accordingly, this study was performed to determine whether
administration of rt-PA to patients with acute myocardial
infarction results in activation of the complement system in
VIVO.
The study was performed in 12 patients with documented
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acute myocardial infarction. The plasma level of various
complement components was analyzed serially before and
after arteriography and after administration of rt-PA. Be-
cause of the large amount of complement proteins normally
present in the blood, there can be acute activation of com-
plement without measurable changes in the levels of com-
ponent s C3 and C4. Therefore, in addition to determining
the concentrations of C3 and C4, we also measured C4a,
C3a and C5a (the anaphylatoxins) . Because these peptides
are normally present in small quantities and are produced
when the complement cascade is activated, their concen-
tration is a more sensitive marker of complement activation
than are the levels of C3 and C4 (6).
Methods
Study patients. The study group consisted of 12 patients
who were enrolled in the National Heart, Lung, and Blood
Institute Thrombolysis in Myocardial Infarction (TIMI) trial
(1) . Criteria for enrollment included age <76 years, chest
pain consistent with myocardial ischemia lasting for :::=::30
minutes and O. I mV ST segment elevation in at least two
electrocardiographic (ECG) leads. Patients were enrolled
within 7 hours from the onset of pain . Myocardial infarction
was confirmed by elevated plasma creatine kinase, MB frac-
tion (MB CK) activity in all patients .
Protocol. Cardiac catheterization was performed in all
patients using the Judkins technique. Heparin (5,000 U) was
given intravenously before any contrast medium injection
and blood sample collection. The protocol consisted of left
ventriculography followed by arteriography of the nonin-
farct-related coronary artery and then of the infarct-related
artery. Only patients with complete occlusion of the infarct-
related artery received recombinant tissue plasminogen ac-
tivator (rt-PA). Six of the 12 patients were found to have
a completely occluded infarct-related artery and were given
rt-PA . In these patients repeat arteriograms of the infarct-
related artery were obtained 30, 60 and 90 minutes after the
initiation of rt-PA therapy . Samples of arterial blood for
assay of the complement components C3, C4, C3a, C4a
and C5a were obtained before and after arteriography of the
infarct-related artery, imniediately after the start of rt-PA
infusion and then serially 5 to 15 minutes after each repeat
arteriographic study up to 90 minutes after rt-PA adminis-
tration . Measurements were included in this study only as
long as the arteriograms obtained after collection of the
samples demonstrated persisting complete obstruction of the
infarct-related artery. This ensured that the complement val-
ues were not affected by reperfusion.
Because of changes in the TIMI protocol, the six patients
treated with rt-PA received different intravenous doses of
the drug . One patient received 40 mg of rt-PA over I hour
and then 20 mglh for 2 hours (total dose 80 mg). Two
patients received a 6 mg bolus of rt-PA followed by 54 mg
over I hour and then 20 mglh for 2 hours (total dose 100
mg). Three patients received a 9 mg bolus followed by 81
mg over the first hour, 20 mg over the second hour and 10
rng/h for the ensuing 4 hours (total dose 150 mg).
The remaining six patients were found to have a patent
infarct-related artery on the initial arteriogram and were not
given rt-PA. These patients served as a control group . In
this cohort, samples for C3, C4, C3a, C4a and C5a assay
were obtained before and after arteriography of the infarct-
related artery and every 5 to 15 minutes, up to 30 minutes,
after arteriography of the infarct-related artery.
In most patients, multiple (up to four) measurements of
complement components were obtained before arteriog-
raphy of the infarct-related artery, after arteriography of the
infarct-related artery and after rt-PA administration. For the
sake of clarity, the results of these multiple determinations
were pooled before arteriography, after arteriography and
after rt-PA, and the mean of each subset of values was used
to express the concentrations of complement components
during these intervals .
Complement component assay. All blood samples (6
to 8 ml) were collected in vials containing disodium ethyl-
enediaminetetraacetic acid. Immediately after collection ,
the specimens were placed on ice and the plasma was sep-
arated in a refrigerated centrifuge . The specimens were then
frozen at - 70°C until analysis was performed . The con-
centration of C4 and C3 was measured using a rate-limited
nephelometric immunoassay (Beckman Immunochemistry
System). Values of the anaphylatoxins C4a , C3a and C5a
were determined by radioimmunoassay using a commer-
cially available kit (Upjohn Co .) (7,8). Normal values in
our laboratory are 75 to ISO mg/dl for C3, 13 to 35 mgldl
for C4, 136 to 680 nglml for C4a, 44 to 116 nglml for C3a
and < 10 nglml for C5a.
Statistics. All values are expressed as mean ± SEM .
Means were compared by the paired or unpaired Student's
t test, as appropriate.
Results
Measurements of C4 and C3. The initial values for C4
and C3 were normal in all 12 patients. Table I shows the
values in the control group and in the rt-PA-treated group .
There was no significant change in C3 or C4 in either group
during the course of the study.
Measurements of C4a, C3a and CSa in the control
group (Fig. 1). The baseline values of C4a (409 ± 111
nglml) , and C5a (8 .8 ± 1.8 ng/ml) were within normal
limits in these six patients , whereas there was a slight in-
crease in the values ofC3a (204 ± 6.6 ng/ml). These values
were obtained a mean of 26 ± 9 minutes before arteriog-
raphy of the infarct-related artery and 253 ± 25 minutes
after the onset of chest pain. After arteriography of the
infarct-related artery there was a slight decrease in all three
ixcc Vol. 10. No.3
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C4 (mg /dl)
Control Grou p (n = 61
C3 (mg/dl)
Before arteriography of infarct-related artery
Afterarteriography of infarct-related artery
23 :': 4
I lJ :': .1
122 :': X
113 :': 6
rt-PA-Treated Group (n = 6 )
Before arteriography of infarct-related artery
After rt-PA
I X :': 4
17 :': 2
101 :': 3
104 :': 4
Values are mean:': SEM. rt-PA = recombinant ti ssue plasminogen activator.
ana phylatoxins (C4a = 224 ± 37 ng/rnl ; C3a = 164 ±
35 ng/ml: and C5a = 7.3 ± 1.3 ng/rnl ) . These values were
obta ined 14 ± 2 minutes after arteri ography of the infarct
arte ry . In four patients, addition al late measurements were
obtained a mean o f 25 ± 3 minutes after arteriog ra phy of
the infarct arte ry. These va lues (C4a = 203 ± 23 ng/rnl ;
C3a = 112 ± 12 ng/ml ; and C5a = 5 .6 ± 1.6 ng/ml)
were lower than the pre viou s measurements. Thus. no in-
crease in plasm a conce ntra tion of ana phy la tox ins was ob-
served during the course of the cardiac ca the terization and
after dye inject ion s in these pat ients who were not treated
wi th rt-PA .
Figure 1. Plasma concentration (Conc.) of anaphylatoxins in the
six untreated control patients (mean ± SEM). Before angiography
of the " infarct" artery , C4a and C5a were normal and C3a was
only slightly elevated. No increase was observed during the course
of cardiac catheterization. Measurements were obtained 26 ± 9
minutes before arteriography of the " infarct" artery (open bars)
and 14 ± 2 minutes after arteriography of the "infarct" artery
(hatched bars). In addition, in four of the six patients "late "
values were obtained 25 ± 3 minutes after arteriography of the
" infarct" artery (solid bars) . The dashed line represents the upper
limit of normal for C4a, C3a and C5a. The number of patients
studied at each time point is specified above the bar.
Measurements of C4a, C3a and CSa in the rt-PA
treated group (Fig. 2). As in the co ntro l group, the baseline
valu es of C4a (406 ± 51 ng/rnl ) and C5a (8.1 ± 1.9 ng/ml )
in the six treated patients were normal , whereas there was
a s lig ht increase in C3a (250 ± 76 ng/ rnl) . These values
were obta ined an average of 19 ± 4 m inutes before ar te-
riography of the infarct-re lated artery an d 276 ± 27 m inutes
after the onse t of pain . Repeat compleme nt va lues (C4a =
3 17 + 126 ng/ml : C3a = 137 ± 43 ng/rnl : and C5a =
6 .7 ± 1.5 ng/rnl ) were obtai ned an ave rage of 13 ± 3
Figure 2. Plasma concentrations (Conc.) of anaphylatoxins in the
six patients given rt-PA (mean ± SEM) . Before angiography of
the " infarct" artery (open bars) the values of C4a and C5a were
normal and C3a was only slightly increased . No significant change
was observed after arteriography of the " infarct" artery (hatched
bars). A striking increase in all three anaphylatoxins, however.
was observed after rt-PA (solid bars). Measurement s were ob-
tained at the following time points: 19 ± 4 minutes before arte-
riography of the "infarct" artery (open bars), 13 ± 3 minutes
after arteriography of the " infarct" artery (hatched bars) and 30
± 4 minutes after rt-PA (solid bars). The dashed line represents
the upper limit of normal for each anaphylatoxin. The number of
patients studied at each time point is specified above the bar. The
p values refer to the differences between levels obtained before
angiography of the "infarct" artery and after rt-PA.
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minutes after arteriography of the infarct-related artery in
four patients. Similar to the pattern in the control group,
these values tended to be lower than those measured before
arteriography. There was no discernible difference in any
of the complement measurements between the rt-PA group
and the control group either before or after arteriography of
the infarct-related artery.
Administration of rt-PA was followed by a striking in-
crease in C3a, C4a and C5a. The greatest change occurred
in C4a, which increased from 317 ± 126 to 2,265 ± 480
ng/rnl (p < 0.01). C3a increased from 137 ± 43 to 600 ±
89 ng/ml (p < 0.05) and C5a from 6.7 ± 1.5 to 30.0 ±
4 .5 ng/ml (p < 0.05) . These values were obtained an av-
erage of 30 ± 4 minutes after initiation of rt-PA infusion
and 48 ± 4 minutes after arteriography of the infarct-related
artery .
The values for C3a, C4a and C5a in individual patients
are demonstrated in Figure 3 . Before administration of rt-
PA , there was no consistent change in individual levels of
anaphylatoxins . After administration of rt-PA, however, an
immediate increase in C4a, C3a and C5a was consistently
observed in all patients. To exclude the possibility that this
phenomenon reflected differences in the timing of samples
between control and treated groups, we compared the results
obtained in the two cohorts at corresponding intervals from
arteriography of the infarct-related artery. In the four pa-
tients in which post-rt-PA measurements were obtained 22
± 2 minutes after arteriography of the infarct-related artery,
the values for C4a (1,665 ± 465 ng/rnl), C3a (351 ± 67
ng/ml) and C5a (16.5 ± 3.6 ng/m!) were considerably greater
than those measured 25 ± 3 minutes after arteriography of
the infarct-related artery in the control group (C4a: 203 ±
22 ng/ml ; C3a: 112 ± 13 ng/ml ; and C5a: 5.6 ± 1.6 ng/ml) .
Three different dosages ofrt-Pn were used in the treated
group . Comparison of the values of C4a, C3a and C5a with
each dose regimen revealed no discernible trend suggesting
a relation between the dose of rt-PA and the magnitude of
complement activation as assessed by the rise in anaphyl-
atoxin concentration. However, the small sample size pre-
cludes any definitive conclusions.
Figure 3. Time course of plasma anaphylatoxin concentration
(Cone) in individual patients given recombinant tissue plasminogen
activator (rt-PA) . The upper panel represents C5a values , the
middle panel C3a values and the lower panel C4a values . Note
that the vertical scale is interrupted for C3a and C5a. Striking
increases in all three anaphylatoxins occurred within minutes of
administration of rt-PA .
Discussion
This study demonstrates that administration of recom-
binant tissue plasminogen activator (rt-PA) is associated
with an immediate and marked activation of the complement
system as reflected by elevations of C4a, C3a and C5a.
These elevations persist for up to 90 minutes after rt-PA
administration. Because all measurements were obtained
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Figure 4. Schematicrepresentationof complement activation (see
text for explanation).
before any angiographic evidence of coronary artery reca-
naliz ation, the rt-PA-induced activ ation of the complement
cascade appears to be independent of reperfusion. The lack
of increa se in anaphylatoxins in control patients subjected
to heparin administration and repeated contrast medium in-
jections indicates that the rise in C3a , C4a and C5a observed
in the rt-PA-treated group was not the result of cardiac
catheterization as such.
Sequence of complement activation (Fig. 4). Plasmin
can directly activate C I, which initiates the classic com -
plement cascade . This nonantigen- antibody activation of C I
is an example of fluid phase co mplement activation. After
C I there is activation of C4, which liberates the anaphyl -
atoxin C4a. C2 is then activated, followed by C3, which
produces C3a and C3b. C3 is an important step in the com -
plement cascade because one of its products , C3b. can fur-
ther activate C3 , thereby cau sing an amplification loop : in
fluid phase activation , howe ver , th is amplifi cation loop is
characteristically inhibited because of the increased acti vity
of the C3b inhibitory protein (9. 10) . Therefore , the increase
in C3a and C5a would be expected to be relati vely less in
fluid phase activation as compared with antigen- ant ibody-
induced activation . Once acti vated , C3 can acti vate C5 to
produce C5a. After C5 activation. the complement cascade
continues to completion with the production of the C5b .6 ,7,8, 9
complex (membrane attack complex) .
In this study, the major incre ase among the anaphyla-
toxins after rt-PA (re lative to preangiography values) was
observed for C4a , the initial anaph ylatoxin produced in the
complement cascade. There was relativel y less produ ction
of C3a and C5a, the second and third anaphylatoxins gen-
erated in the complement cascade, respectively. As dis-
cussed earlier, this pattern of decreasing activation of the
complement cascade from C4 to C5 is consistent with a
fluid phase activation of the complement system.
Relation between dose of rt-PA and complement ac-
tivation. Because of the small number of patients with each
dru g dose, we were unable to establi sh whether a relati on
exis ts between the amount of complement activation and
the dose of rt-PA . Because activation of complement and
clot lysis are both mediated by the same enz yme (plasmin),
it is possible that the level of complement activation may
rellect the amount of thrombolytic acti vity. Accordingly,
measurement of plasma anaphylatoxin levels may be useful
in that it may provide a nonin vasive index of the therapeutic
activity of rt-PA . Thi s potenti ally important implication of
our findings will require confirmation in future studies.
Complement activity in acute myocardial infarction.
Although acute myocardial ischemia is associated with ac-
tivation of the complement system in experimental animals
( I I), it is unknown whether a similar phenomenon occurs
in humans during the initial hour s after the onset of acute
myocardial infarction. Previous studies in patients (12, 13)
have evaluated the complement system I to 7 days after the
onset of infarction and have shown increased complement
activity at these time s. Based on clinical and experimental
data , howe ver , it would appe ar that myocardial necrosis is
completed within 4 to 5 hours after coronary artery occlusion
( 14) . In exploring the potenti al pathogenetic role of the
co mplement system in myocellul ar injur y, it is important to
determine whether complement activation occurs during this
critical interva l. In the present study . the first complement
sample was ohtained an ave rage of 276 ± 27 minut es after
the onset of chest pain in the rt-PA group and 253 ± 25
minut es in the control group. At these time point s there was
no significant ele vation of C4a or C5a and there was onl y
a slight increase in C3a in both the control and rt-PA groups.
It is possible that this pattern resulted from an earlier ac-
tivation of the complement cascade that had almost resolved
because of the short half-life of the anaphylatoxins. It is
also possible that a locali zed complement reaction in the
myocardium may not generate sufficient C4a, C3a and C5a
to be dete cted in the systemic circulation. Thu s , we cannot ,
on the basis of the present data , exclude significant act i-
vation of complement in the early phase of myocardial in-
farct ion .
Significance of rt-PA-induced complement activa-
tion. Considerable experimental evidence suggests that
complement activation may be detrimental in the setting of
acute myocardial ischemia. Anaph ylatoxins have been dem-
onstrated to cause white blood cell clumping, acti vation and
migration in vitro as well as in vivo (6 , 15) . Complement-
medi ated influx of inflammatory cells into reperfused myo-
cardium may extend the amount of necrosis initiall y caused
by ischemia and play an important role in the so called
" reperfusion injury" (14,1 6). Indeed , recent data suggest
that activated leukocytes exacerbate myocardial injury as-
sociated with ischemia and reflow (16). Leukocytes can
obstruct ischemic capillaries, causing the "no reflew" phe-
nomenon after reperfusion (17) and can release cytotoxic
C6C7
C423 ;.g;.9 •C5b-9
C5 C5a Membrane
Attack
Complex
C3a
C3
C3b Am~:::,atlOn
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oxygen-free radicals, lyticenzymes and leukotrienes, which
may mediate reperfusion injury (16). In addition, depletion
of complement has been demonstrated to decrease infarct
size in dogs (18) and baboons (19). It is unknown, however,
whether the level of anaphylatoxin production induced by
rt-PA is sufficient to cause activation of leukocytes and to
produce any deleterious influence on the extent of injury
during myocardial infarction in humans. Nevertheless, char-
acterization of the potential nonspecific effects of plasmin
warrants further investigation , particularly in view of the
widespread use of thrombolytic therapy.
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